Imprimir Ver referencias Citación AMA Citation Lennon J, Shah R. Lennon J, Shah R Lennon, Jack, and Ravi Shah. "Comparison of Cardiovascular and Safety Outcomes of Chlorthalidone vs Hydrochlorothiazide to Treat Hypertension." 2 Minute Medicine, 3 marzo 2020. McGraw-Hill, New York, NY, 2020. AccessMedicina. http://accessmedicina.mhmedical.com/updatesContent.aspx?gbosid=534086§ionid=240844521 MLA Citation Lennon J, Shah R. Lennon J, Shah R Lennon, Jack, and Ravi Shah.. "Comparison of Cardiovascular and Safety Outcomes of Chlorthalidone vs Hydrochlorothiazide to Treat Hypertension." 2 Minute Medicine New York, NY: McGraw-Hill, 2020, http://accessmedicina.mhmedical.com/updatesContent.aspx?gbosid=534086§ionid=240844521. Descargar archivo de la citación: RIS (Zotero) EndNote BibTex Medlars ProCite RefWorks Reference Manager Mendeley © Copyright Clip Capítulo completo Sólo figuras Sólo cuadros Solo Videos Supplementary Content Arriba Comparison of Cardiovascular and Safety Outcomes of Chlorthalidone vs Hydrochlorothiazide to Treat Hypertension by Jack Lennon, Ravi Shah Listen +Originally published by 2 Minute Medicine® (view original article). Reused on AccessMedicine with permission. +1. While chlorthalidone is the recommended thiazide diuretic treatment for hypertension, it has no added benefits compared to hydrochlorothiazide and has significantly worse safety profile. +Evidence Rating Level: 1 (Excellent) +The American College of Cardiology/American Heart Association hypertension guideline reported in 2017 that the recommended thiazide diuretic treatment for hypertension is currently chlorthalidone. However, there are insufficient trials investigating risks and benefits. This Large-Scale Evidence Generation and Evaluation in a Network of Databases (LEGEND) observational, comparative cohort study sought to investigate the cardiovascular and safety outcomes of chlorthalidone and hydrochlorothiazide as first-line treatments for hypertension. Of 730,225 individuals (M [SD] age, 51.5 [13.3] years, 61.6% female), 36,918 were prescribed chlorthalidone with 149 composite outcome events and 693,337 were prescribed hydrochlorothiazide with 3,089 composite outcome events. No significant differences were found in associated risks of stroke, hospitalized heart failure, or myocardial infarction. The hazard ratio for composite cardiovascular outcomes was 1.00 for chlorthalidone compared to hydrochlorothiazide (95% CI 0.85 to 1.17). Chlorthalidone was associated with significantly elevated risks of type 2 diabetes (HR, 1.21, 95% CI 1.12-1.30), chronic kidney disease (HR, 1.24, 95% CI 1.09 to 1.42), acute renal failure (HR, 1.37, 95% CI 1.15 to 1.63), hyponatremia (HR, 1.31, 95% CI 1.16 to 1.47), and hypokalemia (HR, 2.72, 95% CI 2.38 to 3.12). However, chlorthalidone was also associated with a lower risk of abnormal weight gain (HR, 0.73, 95% CI 0.61 to 0.86). This study highlights concerns related to the preferred treatment for hypertension, such that chlorthalidone use not only resulted in non-significant cardiovascular benefits compared to hydrochlorothiazide but was associated with significantly greater risks of metabolite and renal abnormalities. +Click to read the study in JAMA Internal Medicine +©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.